Representativeness of Study Participants from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Published in 2024 by Vivek Subbiah, Niamh Coleman, Sarina A. Piha Paul

, Apostolia M. Tsimberidou, Filip Janku, Jordi Rodon, Shubham Pant, Ecaterina E. Ileana Dumbrava, Siqing Fu, David S. Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload